|
⚲
|
| Brian Atwood | |
|---|---|
| Firm | |
| Address | 201 Haskins Way, Suite 230 South San Francisco, CA 94080 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM ($M) |
|---|---|---|---|---|---|
| CERO Therapeutics Holdings Inc | 021-545301 | Director | 5.0 M of 8.0 M |
||
| CERO Therapeutics Holdings Inc | 021-525940 | Director | 1.2 M of 1.2 M |
||
| CERO Therapeutics Holdings Inc | 021-506000 | Executive Officer | 10.2 M of 10.2 M |
||
| Atreca Inc | 021-321684 | Director | 125.0 M of 125.0 M |
||
| Atreca Inc | 021-293433 | Director | 35.0 M of 35.0 M |
||
| Cell Design Labs Inc | 021-265295 | Executive Officer | 22.9 M of 22.9 M |
||
| Cell Design Labs Inc | 021-265322 | Executive Officer | 4.0 M of 4.0 M |
||
| Phaserx Inc | 021-264676 | Director | of 0.4 M |
||
| Opgen Inc | 021-264019 | Director | 7.2 M of 10.4 M |
||
| Phaserx Inc | 021-254009 | Director | 4.0 M of 4.0 M |
||
| Atreca Inc | 021-252456 | Director | of 0.7 M |
||
| Atreca Inc | 021-252455 | Director | 57.3 M of 57.3 M |
||
| Opgen Inc | 021-244329 | Director | 2.6 M of 2.6 M |
||
| Opgen Inc | 021-234523 | Director | 1.2 M of 1.5 M |
||
| Veracyte Inc | 021-225555 | Director | 12.8 M of 12.8 M |
||
| Opgen Inc | 021-221240 | Director | 1.1 M of 1.5 M |
||
| Immune Design Corp | 021-219014 | Director | 0.0 M of 0.0 M |
||
| Immune Design Corp | 021-218940 | Director | 0.0 M of 0.0 M |
||
| Five Prime Therapeutics Inc | 021-214271 | Director | 21.0 M of 21.0 M |
||
| Opgen Inc | 021-208924 | Director | 4.0 M of 4.0 M |
||
| Phaserx Inc | 021-208169 | Director | of 1.5 M |
||
| Clovis Oncology Inc | 021-207178 | Director | 192.0 M | ||
| Immune Design Corp | 021-205531 | Director | 48.5 M of 57.8 M |
||
| Phaserx Inc | 021-203901 | Director | 1.4 M of 1.4 M |
||
| Phaserx Inc | 021-199468 | Director | 0.5 M of 1.4 M |
||
| Phaserx Inc | 021-188838 | Director | 1.5 M of 3.0 M |
||
| Phaserx Inc | 021-180834 | Director | 1.6 M of 1.6 M |
||
| Five Prime Therapeutics Inc | 021-177000 | Director | 10.0 M of 10.0 M |
||
| Opgen Inc | 021-174955 | Director | 6.1 M of 17.0 M |
||
| Phaserx Inc | 021-173428 | Director | 3.6 M of 4.7 M |
||
| Groove Biopharma Corp | 021-170387 | Director | 4.5 M of 6.0 M |
||
| Opgen Inc | 021-169854 | Director | 3.5 M of 3.7 M |
||
| Trius Therapeutics Inc | 021-160869 | Director | 30.2 M of 44.3 M |
||
| Opgen Inc | 021-148629 | Director | 11.9 M of 15.7 M |
||
| Five Prime Therapeutics Inc | 021-147844 | Director | 7.5 M of 7.5 M |
||
| Immune Design Corp | 021-145953 | Director | 34.0 M of 34.0 M |
||
| Veracyte Inc | 021-143695 | Director | 9.3 M of 28.4 M |
||
| Mirina Corp | 021-141242 | Director | 3.9 M | ||
| Opgen Inc | 021-66404 | Director | 4.0 M of 8.2 M |
||
| Trius Therapeutics Inc | 021-87409 | Director | 19.2 M of 30.0 M |
||
| Helicos Biosciences Corp | 021-61335 | Director | 10.0 M of 10.0 M |
||
| Phaserx Inc | 021-115661 | Director | 1.2 M of 1.2 M |
||
| Immune Design Corp | 021-119253 | Director | 0.0 M of 0.0 M |
||
| Versant Venture Management LLC | |||||
| Versant Affiliates Fund I-A LP | 021-175482 | Director | 5.2 M of 5.2 M |
0.0 | |
| Versant Affiliates Fund I-B LP | 021-175440 | Director | 11.6 M of 11.6 M |
0.1 | |
| Versant Side Fund II LP | 021-175486 | Director | 3.6 M of 3.6 M |
1.2 | |
| Versant Side Fund I LP | 021-175439 | Director | 5.0 M of 5.0 M |
0.4 | |